NASDAQ:CMPX

Compass Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CMPX

*Your capital is at risk

$2.10

+0.0200 (+0.96%)

At Close: Jun 03, 2026

Compass Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -32.19. In total, the insiders bought 16.48M and sold 14.61M CMPX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-32.19
● Buy	16.48M shares
● Sell	14.61M shares
89% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -32.19. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (89% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 29, 2026 Buy	Common Stock P-Purchase	Lerner Neil Chief Accounting Officer	Officer	15 000 Value: $28.4K
Apr 29, 2026 Buy	Common Stock P-Purchase	Anderman Jonathan General Counsel	Officer	25 000 Value: $47.3K
Apr 29, 2026 Buy	Common Stock A-Award	Lerner Neil Chief Accounting Officer	Officer	15 000 Value: $28.4K
Apr 29, 2026 Buy	Common Stock A-Award	Anderman Jonathan General Counsel	Officer	25 000 Value: $47.3K
Feb 08, 2026 Sell	Common Stock F-InKind	Schuetz Thomas J. Chief Executive Officer	CEO / President	36 687 Value: $239.2K
Jan 09, 2026 Sell	Common Stock F-InKind	Schuetz Thomas J. Chief Executive Officer	CEO / President	46 777 Value: $250.3K
Jan 02, 2026 Buy	Common Stock J-Other	Prasad Arjun Officer	Officer	0 Value: $0
Jan 02, 2026 Buy	Common Stock J-Other	Sirard Cynthia Officer	Officer	0 Value: $0
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Ferneau Philip Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Gordon Carl L Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Boylan James P Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Gray Mary Ann Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	STOCK OPTION (RIGHT TO BUY) A-Award	Prasad Arjun Chief Commercial Officer	Officer	1 000 000 Value: $5.17M
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Schuetz Thomas J. CEO	CEO / President	2 000 000 Value: $10.3M
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Shin Barry CFO	C-Suite Officer	670 000 Value: $3.46M
Jan 02, 2026 Buy	Common Stock A-Award	Shin Barry CFO	C-Suite Officer	125 000 Value: $646.3K
Jan 02, 2026 Buy	STOCK OPTION (RIGHT TO BUY) A-Award	Sirard Cynthia Chief Medical Officer	Officer	1 000 000 Value: $5.17M
Jan 02, 2026 Buy	Common Stock A-Award	Schuetz Thomas J. CEO	CEO / President	250 000 Value: $1.29M
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Lindahl Richard S Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Chiniara Ellen Director	Director	90 000 Value: $465.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Lerner Neil Chief Accounting Officer	Officer	435 000 Value: $2.25M
Jan 02, 2026 Buy	Common Stock A-Award	Lerner Neil Chief Accounting Officer	Officer	62 500 Value: $323.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Anderman Jonathan General Counsel	Officer	720 000 Value: $3.72M
Jan 02, 2026 Buy	Common Stock A-Award	Anderman Jonathan General Counsel	Officer	150 000 Value: $775.5K
Nov 16, 2025 Sell	Common Stock F-InKind	Schuetz Thomas J. Chief Executive Officer	CEO / President	44 025 Value: $212.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COMPASS THERAPEUTICS, INC.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that i...

Read Full Profile Here